Zyla Life Sciences logo

ZCOR - Zyla Life Sciences Share Price

$2.05 0.0  0.0%

Last Trade - 18/05/20

Sector
Healthcare
Size
Micro Cap
Market Cap £15.8m
Enterprise Value £86.8m
Revenue £66.3m
Position in Universe th / 6317
Bullish
Bearish
Unlock ZCOR Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Financial Summary
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Zyla Life Sciences revenues increased 8% to $19.1M. Net loss totaled $18.2M vs. income of $96.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net loss reflects Reorganization items decrease from $114.6M (income) to $0K, Dummy Code Income Statement increase from $200K to $4M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ZCOR Revenue Unlock ZCOR Revenue

Net Income

ZCOR Net Income Unlock ZCOR Revenue

Normalised EPS

ZCOR Normalised EPS Unlock ZCOR Revenue

PE Ratio Range

ZCOR PE Ratio Range Unlock ZCOR Revenue

Dividend Yield Range

ZCOR Dividend Yield Range Unlock ZCOR Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ZCOR EPS Forecasts Unlock ZCOR Revenue
Profile Summary

Zyla Life Sciences, formerly Egalet Corporation, is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company's products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology. The Company's product SPRIX Nasal Spray, which contains ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level. The Company's product OXAYDO is an approved immediate-release (IR) oxycodone product formulated to deter abuse through snorting. Its product candidate, ARYMO ER is an abuse-deterrent (AD), extended-release (ER), oral morphine formulation. The Company's product candidate, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation.

Directors
Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated August 21, 2013
Public Since February 6, 2014
No. of Shareholders: 3
No. of Employees: 127
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange OTC Markets Group
Shares in Issue 9,611,957
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ZCOR Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ZCOR
Upcoming Events for ZCOR
Frequently Asked Questions for Zyla Life Sciences
What is the Zyla Life Sciences share price?

As of 18/05/20, shares in Zyla Life Sciences are trading at $2.05, giving the company a market capitalisation of £15.8m. This share price information is delayed by 15 minutes.

How has the Zyla Life Sciences share price performed this year?

Shares in Zyla Life Sciences are currently trading at $2.05 and the price has moved by -26.79% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Zyla Life Sciences price has moved by -28.68% over the past year.

What are the analyst and broker recommendations for Zyla Life Sciences?

Of the analysts with advisory recommendations for Zyla Life Sciences, there are there are currently 0 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Zyla Life Sciences is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Zyla Life Sciences next release its financial results?

Zyla Life Sciences is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Zyla Life Sciences dividend yield?

Zyla Life Sciences does not currently pay a dividend.

Does Zyla Life Sciences pay a dividend?

Zyla Life Sciences does not currently pay a dividend.

When does Zyla Life Sciences next pay dividends?

Zyla Life Sciences does not currently pay a dividend.

How do I buy Zyla Life Sciences shares?

To buy shares in Zyla Life Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Zyla Life Sciences?

Shares in Zyla Life Sciences are currently trading at $2.05, giving the company a market capitalisation of £15.8m.

Where are Zyla Life Sciences shares listed? Where are Zyla Life Sciences shares listed?

Here are the trading details for Zyla Life Sciences:

Country of listing: United States
Exchange: OTC
Ticker Symbol: ZCOR
What kind of share is Zyla Life Sciences?

We were not able to load our ranking data for Zyla Life Sciences

Is there a Zyla Life Sciences share price forecast 2020?

Shares in Zyla Life Sciences are currently priced at $2.05. At that level they are trading at 26.83% premium to the analyst consensus target price of 0.00.

Analysts covering Zyla Life Sciences currently have a consensus Earnings Per Share (EPS) forecast of -0.07 for the next financial year.

How can I tell whether the Zyla Life Sciences share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Zyla Life Sciences. Over the past six months, the relative strength of its shares against the market has been -6.19%. At the current price of $2.05, shares in Zyla Life Sciences are trading at -3.98% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Zyla Life Sciences PE Ratio?

We were not able to find PE ratio data for Zyla Life Sciences.

Who are the key directors of Zyla Life Sciences?

We were unable to find the directors for Zyla Life Sciences.

Who are the major shareholders of Zyla Life Sciences?

Here are the top five shareholders of Zyla Life Sciences based on the size of their shareholding:

CR Group Private Equity
Percentage owned: 47.72% (4.59m shares)
Riva Ridge Capital Management LP Investment Advisor
Percentage owned: 9.77% (939k shares)
CI Investments Inc. Investment Advisor/Hedge Fund
Percentage owned: 9.73% (935k shares)
Highbridge Capital Management, LLC Investment Advisor/Hedge Fund
Percentage owned: 9.44% (907k shares)
Tekla Capital Management LLC Investment Advisor
Percentage owned: 6.83% (657k shares)
Similar to ZCOR
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.